Pharmaceuticals company Jubilant Pharmova announced Q3FY26 results Revenue: Rs 2,123 crore against Rs 1,822 crore during Q3FY25, change 17%. EBITDA: Rs 310 crore against Rs 296 crore during Q3FY25, change 5%. EBITDA Margin: 14.5% for Q3FY26. PAT: Rs 86 crore against Rs 104 crore during Q3FY25, change -17%. PAT Margin: 4% for Q3FY26. Shyam S Bhartia, Chairman & Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova, said: “We are pleased to announce revenue of Rs 2,123 crore for Q3FY26, which reflects a solid growth of 17% on YoY basis. Revenue growth is particularly driven by incremental revenue generation from the new & third line in CDMO Sterile Injectable business. We expect this growth momentum to continue as we make progress in the last quarter of current financial year. EBITDA for the period grew by 5% YoY to Rs 310 crore due to improved performance in CDMO Sterile Injectables and CRDMO business. Normalised PAT for the quarter stood at Rs 86 crore As we are consciously investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, Net Debt / EBITDA remains range bound at 1.3x in Dec’25, lower from 1.5x in Sep’25. During Q3FY26, we saw exceptional growth momentum in the Ruby-Fill® installs. In the Allergy Immunotherapy business, we witnessed increase in demand from the US market. In the CDMO Sterile Injectables business, we ramped up revenue generation from technology transfer programs at Line 3 in Spokane. In the CRDMO business, we continue to invest in building CDMO capabilities. In the Generics business, we are foreseeing growth & profitability improvement. Lastly, in our Proprietary Novel drugs business, we continue to make progress in JBI-802 and JBI-778 clinical trials. During the quarter, we witnessed a decline in EBITDA margins, primarily due to the temporary shutdown of our CDMO Sterile Injectables facility in Montreal for remediation following FDA observations. Production has resumed at our Montreal site in Q4FY26. We anticipate EBITDA margins to strengthen going forward, effectively offsetting higher depreciation costs and driving net profit growth.” Result PDF